Jeffrey Depp joins a Federalist Society panel with Alden Abbott, Jane Bambauer and Satya Marar on intellectual property, AI training and fair use.

In the Washington Examiner, CFJ's Ashley Baker warns that Brazil's Europe-style digital rules punish American tech companies and open the door to China.

The Committee for Justice, along with the Manhattan Institute, joined an amicus brief by the Buckeye Institute urging the Supreme Court to grant certiorari in Newman v. Moore, a case that raises fundamental questions about judicial independence and the Constitution’s separation of powers…

In IPWatchdog, CFJ's Jeffrey Depp argues that by taking Hikma v. Amarin, the Supreme Court chose a narrow skinny-label fight over the patent questions that matter.

In Truth on the Market, CFJ's Jeffrey Depp argues that non-binding AI term sheets invite firms to cluster around what Washington favors.

In Truth on the Market, CFJ's Jeffrey Depp argues that Hikma v. Amarin reflects a fatal conceit: the belief that courts and regulators can engineer cheaper drugs.

No government, federal or state, knows enough to regulate artificial intelligence. Why markets, not mandates, should govern AI.

In Truth on the Market, CFJ's Jeffrey Depp argues that trade enforcement, not imported foreign price controls, is the right answer to high U.S. drug prices.

The Committee for Justice has submitted comments to the Centers for Medicare & Medicaid Services opposing the proposed GLOBE and GUARD models, which would tie certain Medicare drug payments to prices set in foreign countries…